Head, Department of Oncology
- Professor of Experimental Cancer Medicine
- Consultant Medical Oncologist, Oxford Cancer and Haematology Centre
My research concentrates on the development of new cancer drugs and on the treatment of melanoma.
Mark Middleton is Professor of Experimental Cancer Medicine in the Department of Oncology, consultant Medical Oncologist at the Oxford Cancer and Haematology Centre and Head of the Department of Oncology at the University of Oxford.
Mark is the Lead Cancer Clinician for the Oxford University Hospitals NHS Foundation Trust and Director of the Cancer Research UK Oxford Centre. He directs the EPCTU and the Cancer Theme of the NIHR Biomedical Research Centre.
He studied medicine at Cambridge and Oxford and trained in medical oncology at the Christie Hospital. Mark is a member of the International Melanoma Working Group and of the NCRI Melanoma Clinical Studies Group. He leads several clinical trials in the national portfolio.
Adjuvant whole brain radiation therapy compared with observation after local treatment of melanoma brain metastases: a multicentre, randomized phase 3 trial
MIDDLETON M. et al, (2019), Journal of Clinical Oncology
Peris K. et al, (2019), Eur J Cancer, 118, 10 - 34
Findlay JM. et al, (2019), Eur Radiol
T cell regulation in pancreatic ductal adenocarcinoma
ABU SHAH E. et al, (2019)
Andtbacka RHI. et al, (2019), J Immunother Cancer, 7